Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
iXpressGenes
Huntsville, Alabama, United States
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
iXpressGenes’ TAI™ blood test is being used in clinical partnerships to identify trauma-induced immune and neuroinflammatory dysregulation, supporting early intervention; additional preclinical programs target novel antibiotic discovery from extremophilic microbiome libraries.
- Therapeutic areas
- CardiovascularImmunologyInfectious DiseasesNeurologyPsychiatry
- Modalities
- DiagnosticRNA biomarker analysisRecombinant proteinSmall moleculeEnzyme
- Industry
- Biotech
02
Partnerships
Birmingham VA Medical CenterKids to Love FoundationWellStonegBETA Huntsville (gener8tor accelerator)HudsonAlpha Institute for Biotechnology
Beyond the preview
Go deeper on iXpressGenes.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iXpressGenes.